Analyst Price Targets — GILD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 23, 2026 8:23 am | Akash Tewari | Jefferies | $185.00 | $157.19 | StreetInsider | Gilead Sciences (GILD) PT Raised to $185 at Jefferies |
| October 12, 2026 10:17 am | — | Raymond James | $164.00 | $151.17 | StreetInsider | Gilead Sciences (GILD) PT Raised to $164 at BofA Securities |
| October 8, 2026 12:45 pm | Brian Abrahams | RBC Capital | $126.00 | $145.64 | TheFly | Gilead price target raised to $126 from $123 at RBC Capital |
| October 7, 2026 12:59 pm | — | Truist Financial | $158.00 | $147.53 | TheFly | Gilead price target raised to $158 from $150 at Truist |
| September 10, 2026 10:23 am | Morten Herholdt | HSBC | $175.00 | $145.65 | TheFly | Gilead price target raised to $175 from $155 at HSBC |
| August 5, 2026 12:43 pm | — | Truist Financial | $150.00 | $132.76 | TheFly | Gilead price target lowered to $150 from $156 at Truist |
| August 5, 2026 11:41 am | — | RBC Capital | $123.00 | $135.25 | TheFly | Gilead price target raised to $123 from $120 at RBC Capital |
| July 29, 2026 9:07 am | — | Barclays | $145.00 | $134.32 | TheFly | Gilead price target lowered to $145 from $155 at Barclays |
| July 27, 2026 12:07 pm | — | Morgan Stanley | $165.00 | $131.23 | TheFly | Gilead price target lowered to $165 from $166 at Morgan Stanley |
| July 20, 2026 8:18 pm | Daina Graybosch | Leerink Partners | $127.00 | $133.21 | TheFly | Gilead downgraded to Market Perform from Outperform at Leerink |
Latest News for GILD
Gilead Sciences heads into Q3 earnings with strong HIV sales, Yeztugo momentum and expanding oncology prospects, but competitive pressures warrant caution.
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.
Citizens Financial Group Inc. RI boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 52.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,063 shares of the biopharmaceutical company's stock after purchasing an additional
Amgen and Gilead pay forward dividend yields above 2%. Gilead has a lower dividend payout ratio, but Amgen is generating stronger sales growth.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.